Ruggie Capital Group adds Pacira Pharmaceuticals Inc (PCRX) to its portfolio

Pacira Pharmaceuticals Inc (PCRX) : Ruggie Capital Group added new position in Pacira Pharmaceuticals Inc during the most recent quarter end. The investment management firm now holds 574 shares of Pacira Pharmaceuticals Inc which is valued at $26,123 , the company said in a statement filed on Aug 10, 2016 with the SEC.Pacira Pharmaceuticals Inc makes up approximately 0.02% of Ruggie Capital Group’s portfolio.

Other Hedge Funds, Including , First Mercantile Trust Co sold out all of its stake in PCRX during the most recent quarter. The investment firm sold 9,303 shares of PCRX which is valued $423,380.Teacher Retirement System Of Texas boosted its stake in PCRX in the latest quarter, The investment management firm added 622 additional shares and now holds a total of 5,184 shares of Pacira Pharmaceuticals Inc which is valued at $223,482. Spectrum Management Group sold out all of its stake in PCRX during the most recent quarter. The investment firm sold 4,018 shares of PCRX which is valued $145,653. Livingston Group Asset Management Co (operating As Southp… added PCRX to its portfolio by purchasing 100 company shares during the most recent quarter which is valued at $3,690.

Pacira Pharmaceuticals Inc closed down -0.8 points or -1.85% at $42.34 with 4,15,543 shares getting traded on Friday. Post opening the session at $43.12, the shares hit an intraday low of $42.083 and an intraday high of $43.1432 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Pacira Pharmaceuticals Inc reported $0.21 EPS for the quarter, beating the analyst consensus estimate by $ 0.16 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $0.05. The company had revenue of $69.60 million for the quarter, compared to analysts expectations of $66.92 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.20 EPS.

Many Wall Street Analysts have commented on Pacira Pharmaceuticals Inc. Pacira Pharmaceuticals Inc was Downgraded by Brean Capital to ” Hold” on Jul 1, 2016. Shares were Reiterated by Wedbush on May 25, 2016 to “Outperform” and Lowered the Price Target to $ 105 from a previous price target of $113 .

Pacira Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is focused on the development commercialization and manufacture of pharmaceutical products based on its DepoFoam drug delivery technology primarily for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. DepoFoam is basis for the company’s lead product candidate EXPAREL a liposome injection of bupivacaine an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL DepoFoam is also the basis for its other commercial product DepoCyt(e) which the Company manufactures for its commercial partners as well as its other product candidates. The Company’s other product candidates include DepoMeloxicam and DepoTranexamic Acid.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Pacira Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pacira Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.